 |
Vol.59 No.2 contents | Japanese/English |
 | Full Text of PDF (4711K) Article in Japanese |
- Case Report -
A Case of Small Cell Lung Cancer with an Epidermal Growth Factor Receptor T790M Mutation That Responded to Osimertinib
Chiaki Matsumoto1, Tomoki Tamura1, Tomoka Kawajiri1, Tatsuya Nishi1, Kenichiro Kudo1, Shoichi Kuyama11Department of Respiratory Medicine, Iwakuni Clinical Center, Japan
Background. Recently, there are few reports of small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation, but, the efficacy of EGFR tyrosine kinase inhibitor (EGFR-TKI) to small cell lung cancer with EGFR gene mutation has been unknown. Here we report a case of a small cell lung cancer with EGFR mutation T790M after the administration of gefitinib, responded to osimertinib. Case. A 65-year-old woman was referred to our hospital and diagnosed as small cell lung cancer (cT2aN0M1b cStage IVB) and we performed as first line carboplatin and etoposide for 6 courses, and we screened EGFR mutations using a multiplex gene diagnostic agent which revealed the presence of an Exon21 L858R mutation from the specimens which was first diagnosed. So we administrated gefitinib when the cancer relapsed. It had been effective for about 3 months. Next, we performed EGFR mutation test and found T790M mutation from the plasma specimen, so we tried osimertinib, the cancer responded well. Conclusion. It was suggested that EGFR-TKI may be one of treatment options of small cell lung cancer with EGFR mutation.
key words: Small cell lung cancer with EGFR-mutation, T790M mutation, Osimertinib
Received: August 7, 2018
Accepted: January 17, 2019
JJLC 59 (2): 151-157, 2019
